Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Astellas Pharma Ltd., SPACE, 68 Chertsey Road, Woking, Surrey, GU21 5BJ, United Kingdom
Flomaxtra XL, 400 micrograms, film-coated prolonged-release tablet.
| Pharmaceutical Form |
|---|
|
Film-coated prolonged-release tablet. Approximately 9 mm, round, bi-convex, yellow, film-coated tablets debossed with the code ‘04’. |
Each tablet contains as active ingredient tamsulosin hydrochloride 400 micrograms, equivalent to 367 micrograms tamsulosin.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Tamsulosin |
Tamsulosin binds selectively and competitively to post-synaptic α1-adrenoreceptors, prevailingly their subtypes designated α1A and α1D. Thus relaxation of smooth muscles of the prostate and urethra is achieved, which leads to a reduction of tonus and an improvement of the urinary flow. |
| List of Excipients |
|---|
|
Core: Macrogol (containing butylhydroxytoluene) Film-coat: Hypromellose |
Aluminium foil blister packs containing 30 tablets.
Astellas Pharma Ltd., SPACE, 68 Chertsey Road, Woking, Surrey, GU21 5BJ, United Kingdom
PL 00166/0199
Date of first authorisation: 11 July 2005
Date of latest renewal: 07 April 2009
| Drug | Countries | |
|---|---|---|
| FLOMAXTRA | Australia, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
